Ulka N. Vaishampayan, MD of Karmanos Cancer Institute explains why chemotherapy has no role for patients with kidney cancer. She…
Browsing: Acute Lymphoblastic Leukemia
Ulka N. Vaishampayan, MD of Karmanos Cancer Institute discusses the research that she thought was most intriguing at Annual Meeting…
At Patient Power’s 2016 town meeting at Levine Cancer Institute in Charlotte, Dr. Srdan Verstovsek explains why MPNs cause night…
Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how emerging data on resistance has changed treatment for…
Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how CHAARTED and STAMPEDE impacted his treatment for patients…
Neal D. Shore, MD, FACS of Carolina Urologic Research Center discusses how and where chemotherapy fits into treating patients with…
Neal D. Shore, MD, FACS of Carolina Urologic Research Center gives his take on which metastatic castration-resistant prostate cancer patients…
Neal D. Shore, MD, FACS of Carolina Urologic Research Center explains how BRCA1 and BRCA2 genetic testing are significantly changing…
Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas discusses the medical benefits of finding and nourishing hope, which…
Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas advises on how to focus on hope for the best…
Wendy S. Harpham, MD, FACP of Presbyterian Hospital of Dallas explains why there is no one or right approach to…
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses potential approaches physicians should consider when treating metastatic…
Marcus Butler, MD, from the Princess Margaret Cancer Centre, Toronto, Canada, discusses data on the efficacy of pembrolizumab treatment in…
Patrick Miqueu, PhD, from the Jules Bordet Institute in Brussels, Belgium, describes a pilot project to improve the collaboration and…
Lydia Makaroff, PhD, from the European Cancer Patient Coalition, introduces the coalitions new position paper, The Value of Innovation in…
Scott Murray, MD, FRCGP, FRCP Edin from the University of Edinburgh, Edinburgh, Scotland, discusses the talk he gave on different…
Richard Neal, MB, ChB, PhD, FRCGP, from the Leeds Institute of Health Sciences, Leeds, UK, discusses his talk on reducing…
Katsuo Usuda, MD, PhD, from Kanazawa Medical University, Ishikawa, Japan argues that diffusion-weighted magnetic resonance imaging (DWI, MRI) will soon…
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how hopeful he is when it comes to…
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses which non-metastatic renal cell cancer patients should receive…
Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are changing the way…
Matthew I. Milowsky, MD of North Carolina at Chapel Hill School of Medicine discusses how genomics are helping us understand…
Matthew I. Milowsky, MD of University of North Carolina at Chapel Hill School of Medicine discusses his presentation, “Urothelial Carcinoma:…
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives his take on the most promising data coming out of…
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses presentations he found interesting at the symposium, specifically David J.…
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of the upcoming treatment trends for genitourinary cancers…
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital discusses his presentation, “Orphan Cancers with Opportunities for Improved Treatment (ARS)”…
Jeffrey M. Holzbeierlein, MD of University of Kansas Hospital gives an overview of his presentation “Orphan Cancers with Opportunities for…
James Brugarolas, MD of UT Southwestern Medical Center gives an overview of the new kidney cancer research that was presented…
James Brugarolas, MD of UT Southwestern Medical Center discusses the use of targeted therapies in treating non-clear cell renal cell…
Freddie C. Hamdy, MD of University of Oxford gives an overview of the new research that was discussed regarding prostate…
Freddie C. Hamdy, MD of University of Oxford gives his take on which choice would warrant over the others when…
Freddie C. Hamdy, MD of University of Oxford discusses the how surgery, radiation, and active surveillance arms of the ProtecT…
Freddie C. Hamdy, MD of University of Oxford discusses the results of the ProtecT study, which was presented at the…
Freddie C. Hamdy, MD of University of Oxford gives an overview of how the ProtecT study was designed for prostate…
Mohamad E. Allaf, MD of Johns Hopkins University School of Medicine discusses how immunotherapies are being integrated into treatment for…
Eric Jonasch, MD of MD Anderson Cancer Center gives an overview of how targeted therapies are being used in treating…
Eric Jonasch, MD of MD Anderson Cancer Center discusses what approaches should physicians consider when treating patients with metastatic non-clear…
Eric Jonasch, MD of MD Anderson Cancer Center discusses the use of adjuvant therapy to treat patients with non-metastatic renal…
James Brugarolas, MD of UT Southwestern Medical Center gives his take on which non-metastatic renal cell cancer patients should receive…
In this presentation from Lymphoma & Myeloma 2016, Dr. Steven Coutre provides an update on approved tyrosine-kinase inhibitors (TKIs) and…
In this presentation from Lymphoma & Myeloma 2016, Dr. Richard R. Furman discusses the recent FDA approval of venetoclax for…
In this presentation from Lymphoma & Myeloma 2016, Dr. Bruce D. Cheson discusses the role of chemotherapy in the management…
In this presentation from Lymphoma & Myeloma 2016, Dr. Susan Slager discusses the epidemiology of chronic lymphocytic leukemia (CLL), and…
In this presentation from Lymphoma & Myeloma 2016, Dr. Y. Lynn Wang discusses ibrutinib resistance-mechanisms in the treatment of chronic…
In this presentation from Lymphoma & Myeloma 2016, Dr. Jennifer R. Brown discusses the BCR signaling pathway in the treatment…
In this presentation from Lymphoma & Myeloma 2016, Dr. Paul G. Richardson examines how to make sense of the many…
In this presentation from Lymphoma & Myeloma 2016, Dr. Tomer M. Mark discusses monoclonal antibodies in the therapeutic treatment of…
In this presentation from Lymphoma & Myeloma 2016, Dr. Adriana C. Rossi discusses whether second- and third-line agents should be…
This Key Insights activity features conference chair Kathy S. Albain and Dr. Eric P. Winer discussing highlights from the 14th…